What are thymosin beta-4 oxidation degradants on an Australian research certificate?
Thymosin beta-4 oxidation degradants are sequence-related species in which the declared 43-residue, N-acetylated polypeptide has gained one or more oxygen atoms. On a research certificate they are proposed related substances with a mass increment, a chromatographic position and, where the method allows, a residue assignment. Extra area at 214 nm is only a related-substance result. It becomes an oxidation assignment when mass spectrometry shows the oxygen increment and the ion series belongs to the same lot as the parent. The same trade name is sometimes applied to full-length thymosin beta-4 and to the shorter 17-23 sequence sometimes labelled TB-500. An oxidation table calculated for the 43-mer cannot be transferred to a lot whose base peak is the 17-23 fragment. That fragment lacks methionine-6, so a matching +16 Da call would be an identity error. Receiving review should lock the analyte first: acetylated full-length sequence, observed neutral mass, and absence of the short-fragment mass. HPLC area-percent purity does not perform that lock. Reversed-phase methods often leave methionine sulfoxide close to the parent. Incomplete resolution lets ultraviolet integration merge the pair and overstate parent purity, while a single-point mass check on the main peak never sees the shoulder. Report the resolution value, or state that the species was mass-resolved only. A stability-indicating reading needs baseline resolution or an extracted-ion record of the oxidised ion. Certificate language should stay analytical. A lot record may state that an ion is consistent with mono-oxidation. It is not a human-use statement and not a therapeutic-goods release. Concordance of product name, lot number, vial identity, method identifier and report identifier is what lets a later Australian reviewer repeat the assignment. Without those fields, a mass shift is an orphan number.
Which residues can form thymosin beta-4 oxidation degradants?
Native thymosin beta-4 has one methionine, at position 6, and no cysteine, tryptophan, tyrosine or histidine. The expected oxidation degradants are therefore methionine sulfoxide, +15.9949 Da, and methionine sulfone, +31.9898 Da. With only one methionine, a +32 Da species is more economically read as sulfone than as two sulfoxides. A +48 Da ion is outside a methionine-only model and stays unknown unless fragments show a second site. Absent cysteine is a negative control. Disulfide, cysteic acid and sulfenic intermediates are intrinsic risks for cysteine-containing peptides, not for this sequence. An ion series that requires cysteine indicates a wrong analyte, a blend or a labelling error. Tryptophan oxidation products are likewise out of scope unless the labelled sequence is wrong. Keep non-oxygen changes off the oxidation list. Acetyl loss is about -42.0106 Da. Deamidation at asparagine or glutamine is about +0.9840 Da. Sodium adduction, about +21.9819 Da on the neutral mass, is mistaken for oxidation when m/z values are subtracted without a charge-to-neutral conversion. A true oxygen addition gives the same neutral increment at every charge state. Do not average a nominal +16 Da label across charge states; recompute the neutral mass each time. Potassium adduction is a larger neutral increment and fails the same cross-charge test if it is called sulfoxide. Preparation can create sulfoxide after the vial is opened. Peroxide residues in some diluents, dissolved oxygen and trace metals accelerate methionine oxidation in solution. Compare the lot, a qualified reference if available, a diluent blank and a peroxide-stressed aliquot under the same source settings. If the +16 Da ion appears only in stored diluent, record a preparation artefact. That is still an LC-MS identification: it identifies the artefact and stops an unsupported rewrite of the lot attribute.
How does LC-MS identification set charge-state mass windows?
LC-MS identification starts from a calculated neutral mass. For N-acetyl thymosin beta-4, residue masses plus water plus the acetyl increment give a monoisotopic mass of approximately 4960.49 Da. Recompute it from the sequence on the lot record and from the software residue table. A rounded 4963 Da label is an average mass and will mis-set a monoisotopic window. The 43-mer is read as a charge envelope. Using 1.0073 Da per proton, illustrative monoisotopic m/z values are 1241.13 (4+), 993.11 (5+), 827.76 (6+) and 709.65 (7+). These are worked examples, not limits. The report should show observed charge, proton-mass convention and mass error. A sulfoxide addition of 15.9949 Da moves the 4+, 5+, 6+ and 7+ ions by about 3.999, 3.199, 2.666 and 2.285 m/z. A sulfone addition of 31.9898 Da moves them by about 7.997, 6.398, 5.332 and 4.570 m/z. Require the same neutral increment at two or more charge states. A one-charge shift is more consistent with interference or a mis-picked isotope. At m/z 993, 5 ppm is about 0.005 m/z, much smaller than the sulfoxide shift. The usual failure is selecting the wrong isotope, mixing average and monoisotopic maths, or omitting the acetyl group. Omission lowers theory by 42.0106 Da and can make a correct spectrum look like an identity failure. Deamidation, +0.9840 Da, is about 0.197 m/z at charge 5+, beside the 13C spacing of about 0.201 m/z. Unit-resolution data cannot separate those neighbours. State the resolution used, and whether the oxidised species was chromatographically resolved or only mass-resolved. Do not adopt these m/z figures as a specification copied from an unrelated lot.
How do fragment ions locate the oxygen in an LC-MS identification?
Precursor mass gives an oxygen count, not a residue. For thymosin beta-4, fragments that contain methionine-6 must carry the increment, and fragments that exclude it must not. Because methionine is near the amino terminus, acetylated b ions that include position 6 should shift by 15.9949 Da in the sulfoxide, while y ions that exclude position 6 should match the parent map. A +16 Da precursor with entirely unshifted fragments is an unresolved mixture or a bad isolation, not a site assignment. Methionine sulfoxide often loses methanesulfenic acid, 63.998 Da, tracked as a 64 Da neutral loss from the precursor or from Met-containing fragments. The loss supports the assignment when it is absent from Met-free fragments. It does not replace the unshifted C-terminal series. Do not borrow the 64 Da loss for sulfone. A more honest sulfone package is a +31.99 Da precursor, fragments retaining about +32 Da through the Met-containing series, and no sulfoxide-specific loss. If those fragments are missing, record a precursor-only hypothesis. In-source oxidation is tested, not assumed. If a higher source temperature or capillary voltage creates a +16 Da ion absent from a mild-source replicate of the same solution, that portion is an artefact. Paired acquisitions estimate how much of the signal is instrument-generated, because artefact and lot impurity can coexist. Calculators that assume a free amino terminus mis-place the b series by 42 Da. State that fragments were predicted from the acetylated sequence. A minimal confirmatory set is one shifted Met-containing fragment and one unshifted Met-free fragment. Below that set, report a precursor mass match only. Isolate the precursor narrowly enough that the parent isotope cluster is not co-fragmented with the oxidised ion.
How are oxidation degradants separated from deamidation and truncations?
Deamidation is not oxidation. Asparagine-26 and the glutamine residues add about 0.984 Da and convert an amide to a carboxylate. On unit-resolution data the shift hides in the isotope envelope, so a shoulder is often noticed by retention time before accurate mass or a product-ion change supports it. Naming that shoulder as sulfoxide, only because both can sit near the parent, mixes two pathways. Truncation and deletion move mass by a residue or more, not by 16 Da. They belong in the related-substance table and are not thymosin beta-4 oxidation degradants. A missing methionine segment removes the main oxidation site and makes a residual +16 Da search on the wrong base peak uninformative. Hydrolysis products are assigned from their neutral mass loss, not from a forced oxygen hypothesis. The 17-23 fragment must be excluded before degradant naming. It lacks methionine-6, and its intact mass lies near 890 Da rather than near 4960 Da. Include an extracted-ion check for that fragment so a mislabelled vial is failed at identity instead of receiving a 43-mer impurity table. Beta-thymosin literature describes a peptide family, not permission to reuse one member mass as another member specification (PMID:17468232). Thymosin alpha-1 papers describe a different peptide. They do not provide sulfoxide or sulfone windows for thymosin beta-4 (PMID:11381492; PMID:28106477; PMID:30063864). Citing that corpus in place of a beta-4 mass table changes the analyte. Record the negative finding: observed mass inconsistent with thymosin alpha-1, then list oxygen additions only against the acetylated beta-4 mass. Sodium and potassium adducts, and solvent clusters seen in the blank, stay off the oxidation list unless the neutral increment matches oxygen at every observed charge state.
What CoA fields should document LC-MS identification in Australia?
For thymosin beta-4 oxidation degradants, the identity block should name the peptide, state that the amino terminus is acetylated, cite the sequence or a controlled sequence identifier, and list theoretical monoisotopic mass, lot number and report identifier. The LC-MS block should list ion mode, observed m/z, charge, deconvoluted neutral mass, mass error and the calibration check. A line that only says identity confirmed cannot be recomputed. Do not collapse every non-parent peak into one remainder. Each assigned oxidation degradant needs relative retention time, area percent or extracted-ion response, neutral increment, and a flag for fragment-confirmed versus precursor-only. Unknowns above the reporting threshold keep their m/z. State whether sulfoxide and sulfone are summed or limited separately, and state the reporting and identification thresholds. A generic high purity percentage does not imply those thresholds. Name the integration wavelength and whether solvent peaks were excluded from area percent. System suitability should include the parent retention window, resolution from the nearest oxidised peak if resolved, mass accuracy of a check standard, and a blank showing that the +16 Da extracted ion is not carry-over. If ultraviolet purity and LC-MS disagree, say which result governs related substances. Diluent identity, peroxide status if tested, and time from dissolution to analysis explain preparation artefacts. A transport narrative is unnecessary. If fresh diluent removes the sulfoxide, amend the lot table traceably rather than overwriting it. On an Australian research lot, one lot number should link vial label, certificate and chromatogram file. Tracked dispatch shows which lot left the warehouse; it does not characterise the peptide. The pack should state research use only: identity and related-substance review, not a human-use instruction.
Frequently asked questions
Does thymosin beta-4 contain cysteine that can form oxidation degradants?
Native thymosin beta-4 has no cysteine. Disulfide and cysteic-acid pathways are therefore not intrinsic to the declared 43-mer. A cysteine-like mass indicates a wrong analyte, a blend or a label mismatch, and should not be named as a thymosin beta-4 oxidation degradant. The expected oxygen additions are methionine sulfoxide and methionine sulfone at position 6.
What mass shift does LC-MS use for methionine sulfoxide?
Use 15.9949 Da on the neutral mass, not a bare integer, when the instrument is high resolution. At charge 5+ that increment is about 3.199 m/z; at charge 6+ it is about 2.666 m/z. Confirm the same neutral increment on a second charge state. A nominal +16 Da label is only a screening note until charge-state maths and the theoretical acetylated mass agree.
Can HPLC purity alone identify oxidation degradants?
No. Area percent at 214 nm can merge methionine sulfoxide with the parent when resolution is incomplete. Identification needs an oxygen mass increment tied to the lot, preferably with fragment evidence that the oxygen sits on methionine-6. Report relative retention time and whether the species was chromatographically resolved or only mass-resolved. A single purity percentage does not name the degradant.
How is the 17-23 fragment excluded before oxidation assignment?
Check intact mass. The short acetylated fragment lies near 890 Da and lacks methionine-6, whereas acetylated thymosin beta-4 lies near 4960.49 Da. If the base peak matches the fragment, do not issue a 43-mer oxidation table. An extracted-ion check for the fragment mass should sit in the identity section of the method so mislabelling is caught before related substances are named.
Which CoA fields should an Australian laboratory expect?
Expect an acetylated-sequence statement, theoretical monoisotopic mass, observed m/z and charge, neutral mass, mass error, relative retention time of each assigned oxidation degradant, and a flag for fragment-confirmed versus precursor-only. Lot number should match the vial and the chromatogram file. Unknown +16 Da peaks stay unknown until that evidence exists. The document is a research-lot record, not a human-use instruction.
Why are thymosin alpha-1 papers not an oxidation specification?
Thymosin alpha-1 is a different peptide. Papers indexed under that name, including serum-level and review literature, do not tabulate methionine sulfoxide or sulfone windows for the 43-residue beta-4 sequence. Using them as a substitute specification changes the analyte. Beta-4 oxidation degradants are identified from the acetylated beta-4 mass, charge-state increments and fragment localisation, with the alpha-1 mass recorded only as an exclusion.
References
- PMID:17468232 — beta-Thymosins — Ann N Y Acad Sci — 2007
- PMID:11381492 — Thymosin alpha-1 — Am J Health Syst Pharm — 2001
- PMID:28106477 — Thymosin alpha 1 and HIV-1: recent advances and future perspectives — Future Microbiol — 2017
- PMID:30063864 — Serum thymosin alpha 1 levels in normal and pathological conditions — Expert Opin Biol Ther — 2018
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
